LipUm

Cellcolabs is a biotechnology company that production of mesenchymal stromal cells for research and clinical applications.

Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity. Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

The Scibase is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Nevisense is a point-of-care device that has emerged from more than 20 years of academic research at Karolinska Institutet Stockholm and significantly increases the physician’s ability to detect and monitor skin tissue alterations. Nevisense has strong protections through a comprehensive patent portfolio and several other combined approaches that relate to technical and clinical development.

SynAct Pharma AB is developing medications for severe worsening in inflammatory diseases. Their drug candidate AP1189 is designed to treat arthritis, including psoriatic arthritis, a type of acute joint disorder that affects around 30% of psoriasis patients. Preclinical studies indicate that AP1189 can decrease inflammation and speed up healing, potentially reducing joint damage caused by acute joint inflammation. The drug may be administered in tablet form once daily. Results from a phase I clinical study are expected to be released in Q2 2018. The company plans to begin preparations for a patient study while completing the phase I study. If AP1189 proves safe and well-tolerated in multiple doses, the goal is to submit a clinical trial application for patients with active arthritis. Following successful results in patients, SynAct Pharma AB plans to establish commercial partnerships with major pharmaceutical companies.

Pila Pharma is currently in the clinical stage of biotechnology development and focusing on a powerful and specific TRPV1 antagonist known as XEN-D0501. This compound is being studied for its potential in treating type 2 diabetes, obesity, and the rare painful condition erythromelalgia.

Ribocure Pharmaceuticals AB is a biotechnology company specializing in the creation of RNA-based treatments, particularly in the field of oligonucleotide therapeutics. The company is committed to conducting drug discovery and developing clinical trials. It is also involved in global business development initiatives overseen by a Vice President and Head of Global Business Development.

Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge products for the purification and separation of proteins and other molecules. The team at Bio-Works has extensive experience in the biotech industry and in protein purification, and the company is based in Uppsala, Sweden, at the Klövern Business Park site.

Qlucore is a top provider of user-friendly bioinformatics software for research and precision and companion diagnostics. The company aims to simplify the analysis of large and complex data sets from genetics and proteomics fields by offering intuitive visualization-based tools. Their Omics Explorer software is designed for research in various industries and academia, while their Diagnostics software provides AI-powered models for multi-omics diagnostics. Founded in 2007 by researchers at Lund University, Qlucore now serves customers in over 35 countries worldwide. Major pharmaceutical companies, hospitals, and universities use their software for research. To try it for yourself, visit www.qlucore.com.

The company's foundation lies in the initial finding that leukemic stem cells in individuals with chronic myeloid leukemia (CML) exhibit a particular cell-surface receptor that is not present in normal hematopoietic stem cells. Research has also found an increase in this receptor in stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). Cantargia is leveraging this receptor, known as the Interleukin-1 receptor accessory protein (IL1RAP), as the focal point for creating a new antibody-driven treatment for leukemia.

OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in Clinical Affairs, Regulatory and Business Development.

Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in regenerative medicine by converting donated allogeneic tissue into personalized tissue to prevent transplant rejection. Their unique technology platform involves a combination of decellularization and reconditioning/recellularization processes to individualize patient tissue. Verigraft's technology eliminates the need for lifelong immunosuppression. They aim to provide a life-changing impact to patients while benefiting hospitals, healthcare providers, and society on a global scale. Preclinical development and safety data from large animals have been completed for their personalized tissue-engineered vein (P-TEV) product, with plans for clinical development within the next six months.

Gesynta Pharma is a pharmaceutical company in the clinical testing stage that is developing a range of compounds that target the pro-inflammatory enzyme mPGES-1. The company's research is rooted in Karolinska Institutet. Their leading drug candidate, vipoglanstat (GS-248), is currently being developed as a non-hormonal treatment for endometriosis. In preclinical testing on endometriosis, vipoglanstat showed significant reductions in the number of lesions associated with the disease, as well as providing pain relief and improved well-being. Clinical studies have shown that vipoglanstat has a favorable safety profile and promising pharmacological properties, leading to preparations for a phase II study in patients with endometriosis. Endometriosis is a common, painful inflammatory disease that affects about 10% of women of reproductive age, with current treatment options often falling short. Gesynta Pharma, founded in 2017 and located in Stockholm, also has plans for another drug candidate, GS-073, to enter clinical testing in 2023 for a different inflammatory condition. Shareholders in the company include Hadean Ventures, Industrifonden, Linc, and a group of successful life science industry entrepreneurs.